MA-EUSA-PHARMA
EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for QARZIBA® ▼ (dinutuximab beta) was accepted by the China National Medical Products Administration (NMPA) and granted priority review. Dinutuximab beta is a targeted immunotherapy approved by the European Medicines Agency (EMA) for the treatment of high-risk neuroblastoma in patients aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma with or without residual disease. High-risk neuroblastoma is an aggressive neoplasm and the most common childhood solid tumour that originates outside of the brain. Dinutuximab beta is listed in the first batch of New Drugs in Urgent Clinical Need Marketed Overseas by the NMPA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005558/en/
“Dinutuximab beta represents an important biologic, which is already available to patients with high-risk neuroblastoma in Europe,” commented Xiaobin Wu, Ph.D., General Manager of China and President of BeiGene. “For paediatric patients fighting this disease in China, we are hopeful that dinutuximab beta will soon be available as a new treatment option. Our collaboration with EUSA and the progress thus far demonstrate our joint commitment to bringing high-quality therapies to the people who need them.”
Lee Morley, Chief Executive Officer of EUSA Pharma, said, “This milestone brings us and BeiGene closer to delivering on our promise of bringing innovative cancer and rare disease therapies to patients around the world. We look forward to working with BeiGene and the NMPA to potentially make dinutuximab beta available in China.”
About QARZIBA® ▼ (dinutuximab beta)
QARZIBA® ▼ is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells. Dinutuximab beta was approved by the European Commission in 2017 and is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, dinutuximab beta should be combined with interleukin-2 (IL-2).
About EUSA Pharma
Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company has extensive commercial operations in the United States and Europe, alongside a direct presence in select other markets across the globe. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies and is supported by significant funding raised from leading life science investor EW Healthcare Partners. For more information please visit www.eusapharma.com .
About BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,700+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
BeiGene Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential approval, launch and opportunity of QARZIBA® in China, future development and potential commercialization activities of the products under the agreement with EUSA, and other information that is not historical information. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
GL-DNB-2000070. November 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005558/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HP Becomes Sisvel Wi-Fi 6 Pool Licensee, Ending Disputes with Wilus, Huawei and Philips18.11.2025 10:58:00 CET | Press release
HP Inc and Sisvel have concluded an agreement for the Palo Alto-based global technology leader to become a licensee of the Sisvel Wi-Fi 6 patent pool. The deal follows a mediation process ordered by Judge Rodney Gilstrap, of the US District Court for the Eastern District of Texas, as part of patent infringement litigation brought against HP by Wilus Institute of Standards and Technology, a licensor in the pool. The agreement not only ends the Wilus suit, but also actions launched against HP by other Sisvel Wi-Fi 6 pool licensors, Huawei and Philips. HP now has one-stop access to approximately 2,000 patents (245 patent families) recognised to date, through the pool’s process of independent patent evaluations, as essential to the 802.11ax Wi-Fi 6 standard. Close to 40 entities license the patents in the Sisvel Wi-Fi 6 patent pool. In addition to HP Inc, these include other recent additions such as Cisco, Netgear and Acer. “We are grateful to HP for the constructive way in which they enga
Europe's GetVocal raises $26m to scale trustworthy conversational agents for enterprises18.11.2025 10:00:00 CET | Press release
Series A led by Creandum, with Elaia and Speedinvest, will accelerate the product development of GetVocal’s AI customer experience platform GetVocal, Europe’s leading provider of conversational AI agents for enterprise customer support, today announced the closing of a $26 million Series A investment round led by Creandum with participation from Elaia and Speedinvest, bringing GetVocal’s total fundraising to $30 million. GetVocal will use the funding to fuel product innovation, market expansion, and hiring across Europe as the company accelerates its mission to help enterprises build hybrid human-AI workforces. Founded in 2023 by AI entrepreneurs Roy Moussa and Antonin Bertin, GetVocal is headquartered in Paris, with a 60-strong team spread across Europe. It serves 23 markets, with a stronghold in France and Portugal, and a rapidly growing presence in the UK and DACH. The company tackles one of the biggest barriers to conversational AI adoption – the lack of trust and confidence in bla
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release
Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom